140 related articles for article (PubMed ID: 20212335)
21. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.
Kakar Q; Sheikh S; Ahmed I; Khan MA; Jamil M; ElMohammady H; Warsame M
Acta Trop; 2016 Dec; 164():17-22. PubMed ID: 27515812
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy.
Mbacham WF; Evehe MS; Netongo PM; Ateh IA; Mimche PN; Ajua A; Nji AM; Irenee D; Echouffo-Tcheugui JB; Tawe B; Hallett R; Roper C; Targett G; Greenwood B
Malar J; 2010 Jan; 9():34. PubMed ID: 20105282
[TBL] [Abstract][Full Text] [Related]
24. Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyrimethamine combination.
Menemedengue V; Sahnouni K; Basco L; Tahar R
Am J Trop Med Hyg; 2011 Jul; 85(1):22-5. PubMed ID: 21734119
[TBL] [Abstract][Full Text] [Related]
25. High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.
Ojurongbe O; Nguetse CN; Fayemiwo SA; Falade CO; Ojurongbe TA; Thomas BN; Meyer CG; Velavan TP
Pathog Glob Health; 2018 Mar; 112(2):86-92. PubMed ID: 29318942
[TBL] [Abstract][Full Text] [Related]
26. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.
Dorsey G; Vlahos J; Kamya MR; Staedke SG; Rosenthal PJ
J Infect Dis; 2003 Oct; 188(8):1231-8. PubMed ID: 14551894
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.
Maiga H; Djimde AA; Beavogui AH; Toure O; Tekete M; Sangare CP; Dara A; Traore ZI; Traore OB; Dama S; N'Dong C; Niangaly H; Diallo N; Dembele D; Sagara I; Doumbo OK
Malar J; 2015 Feb; 14():64. PubMed ID: 25889633
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran.
Rouhani M; Zakeri S; Pirahmadi S; Raeisi A; Djadid ND
Infect Genet Evol; 2015 Apr; 31():183-9. PubMed ID: 25653131
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.
Tjitra E; Baker J; Suprianto S; Cheng Q; Anstey NM
Antimicrob Agents Chemother; 2002 Dec; 46(12):3947-53. PubMed ID: 12435700
[TBL] [Abstract][Full Text] [Related]
30. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique.
Raman J; Little F; Roper C; Kleinschmidt I; Cassam Y; Maharaj R; Barnes KI
Am J Trop Med Hyg; 2010 May; 82(5):788-94. PubMed ID: 20439956
[TBL] [Abstract][Full Text] [Related]
31. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.
Mishra S; Bharti PK; Shukla MM; Ali NA; Kashyotia SS; Kumar A; Dhariwal AC; Singh N
Pathog Glob Health; 2017 Jun; 111(4):186-194. PubMed ID: 28549390
[TBL] [Abstract][Full Text] [Related]
32. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
[TBL] [Abstract][Full Text] [Related]
33. Molecular survey of Plasmodium falciparum resistance in south-eastern Iran.
Jafari S; Le Bras J; Asmar M; Durand R
Ann Trop Med Parasitol; 2003 Mar; 97(2):119-24. PubMed ID: 12803866
[TBL] [Abstract][Full Text] [Related]
34. Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
Mohapatra PK; Sarma DK; Prakash A; Bora K; Ahmed MA; Sarma B; Goswami BK; Bhattacharyya DR; Mahanta J
PLoS One; 2014; 9(9):e105562. PubMed ID: 25184337
[TBL] [Abstract][Full Text] [Related]
35. Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa.
Nahum A; Erhart A; Ahounou D; Bonou D; Van Overmeir C; Menten J; Akogbeto M; Coosemans M; Massougbodji A; D'Alessandro U
Malar J; 2009 Mar; 8():37. PubMed ID: 19257898
[TBL] [Abstract][Full Text] [Related]
36. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
Sendagire H; Kyabayinze D; Swedberg G; Kironde F
Trop Med Int Health; 2005 Jun; 10(6):537-43. PubMed ID: 15941416
[TBL] [Abstract][Full Text] [Related]
37. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda.
Talisuna AO; Langi P; Mutabingwa TK; Watkins W; Van Marck E; Egwang TG; D'Alessandro U
Trans R Soc Trop Med Hyg; 2003; 97(3):338-42. PubMed ID: 15228255
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union.
Tall A; Rabarijaona LP; Robert V; Bedja SA; Ariey F; Randrianarivelojosia M
Acta Trop; 2007 Jun; 102(3):176-81. PubMed ID: 17568549
[TBL] [Abstract][Full Text] [Related]
39. Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
Sowunmi A; Fehintola FA; Adedeji AA; Gbotosho GO; Tambo E; Fateye BA; Happi TC; Oduola AM
Trop Med Int Health; 2005 Nov; 10(11):1161-70. PubMed ID: 16262741
[TBL] [Abstract][Full Text] [Related]
40. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
Awab GR; Imwong M; Pukrittayakamee S; Alim F; Hanpithakpong W; Tarning J; Dondorp AM; Day NP; White NJ; Woodrow CJ
Malar J; 2016 Feb; 15():121. PubMed ID: 26917051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
